Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
| MER Indicator |
MER description |
Target Fiscal Year |
Target |
| GEND_GBV |
<10, Female, Physical and/or Emotional Violence |
2019 |
147 |
| GEND_GBV |
<10, Female, Sexual Violence (Post-Rape Care) |
2019 |
147 |
| GEND_GBV |
<10, Male, Physical and/or Emotional Violence |
2019 |
147 |
| GEND_GBV |
<10, Male, Sexual Violence (Post-Rape Care) |
2019 |
147 |
| GEND_GBV |
10-14, Female, Physical and/or Emotional Violence |
2019 |
442 |
| GEND_GBV |
10-14, Female, Sexual Violence (Post-Rape Care) |
2019 |
443 |
| GEND_GBV |
10-14, Male, Physical and/or Emotional Violence |
2019 |
146 |
| GEND_GBV |
10-14, Male, Sexual Violence (Post-Rape Care) |
2019 |
152 |
| GEND_GBV |
15-19, Female, Physical and/or Emotional Violence |
2019 |
1,464 |
| GEND_GBV |
15-19, Female, Sexual Violence (Post-Rape Care) |
2019 |
1,469 |
| GEND_GBV |
15-19, Male, Physical and/or Emotional Violence |
2019 |
149 |
| GEND_GBV |
15-19, Male, Sexual Violence (Post-Rape Care) |
2019 |
152 |
| GEND_GBV |
20-24, Female, Physical and/or Emotional Violence |
2019 |
2,057 |
| GEND_GBV |
20-24, Female, Sexual Violence (Post-Rape Care) |
2019 |
2,056 |
| GEND_GBV |
20-24, Male, Physical and/or Emotional Violence |
2019 |
150 |
| GEND_GBV |
20-24, Male, Sexual Violence (Post-Rape Care) |
2019 |
149 |
| GEND_GBV |
25-29, Female, Physical and/or Emotional Violence |
2019 |
442 |
| GEND_GBV |
25-29, Female, Sexual Violence (Post-Rape Care) |
2019 |
440 |
| GEND_GBV |
25-29, Male, Physical and/or Emotional Violence |
2019 |
150 |
| GEND_GBV |
25-29, Male, Sexual Violence (Post-Rape Care) |
2019 |
149 |
| GEND_GBV |
30-34, Female, Physical and/or Emotional Violence |
2019 |
392 |
| GEND_GBV |
30-34, Female, Sexual Violence (Post-Rape Care) |
2019 |
440 |
| GEND_GBV |
30-34, Male, Physical and/or Emotional Violence |
2019 |
150 |
| GEND_GBV |
30-34, Male, Sexual Violence (Post-Rape Care) |
2019 |
149 |
| GEND_GBV |
35-39, Female, Physical and/or Emotional Violence |
2019 |
442 |
| GEND_GBV |
35-39, Female, Sexual Violence (Post-Rape Care) |
2019 |
440 |
| GEND_GBV |
35-39, Male, Physical and/or Emotional Violence |
2019 |
150 |
| GEND_GBV |
35-39, Male, Sexual Violence (Post-Rape Care) |
2019 |
149 |
| GEND_GBV |
40-49, Female, Physical and/or Emotional Violence |
2019 |
442 |
| GEND_GBV |
40-49, Female, Sexual Violence (Post-Rape Care) |
2019 |
440 |
| GEND_GBV |
40-49, Male, Physical and/or Emotional Violence |
2019 |
150 |
| GEND_GBV |
40-49, Male, Sexual Violence (Post-Rape Care) |
2019 |
149 |
| GEND_GBV |
50+, Female, Physical and/or Emotional Violence |
2019 |
151 |
| GEND_GBV |
50+, Female, Sexual Violence (Post-Rape Care) |
2019 |
149 |
| GEND_GBV |
50+, Male, Physical and/or Emotional Violence |
2019 |
146 |
| GEND_GBV |
50+, Male, Sexual Violence (Post-Rape Care) |
2019 |
150 |
| GEND_GBV |
By PEP service provision (related to sexual violence services provided) |
2019 |
1,814 |
| GEND_GBV |
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) |
2019 |
7,341 |
| GEND_GBV |
By type of service: Sexual Violence (Post-Rape Care) |
2019 |
7,344 |
| GEND_GBV |
Number of people receiving post-GBV care |
2019 |
14,687 |
| HTS_SELF |
|
2019 |
82,554 |
| HTS_SELF |
15-19, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
15-19, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
15-19, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
15-19, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
20-24, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
20-24, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
20-24, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
20-24, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
25-29, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
25-29, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
25-29, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
25-29, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
30-34, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
30-34, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
30-34, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
30-34, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
35-39, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
35-39, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
35-39, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
35-39, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
40-49, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
40-49, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
40-49, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
40-49, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
50+, Female, Directly-Assisted |
2019 |
4,422 |
| HTS_SELF |
50+, Female, Unassisted |
2019 |
4,422 |
| HTS_SELF |
50+, Male, Directly-Assisted |
2019 |
1,474 |
| HTS_SELF |
50+, Male, Unassisted |
2019 |
1,474 |
| HTS_SELF |
Directly-Assisted |
2019 |
41,277 |
| HTS_SELF |
FSW, Directly-Assisted |
2019 |
55,311 |
| HTS_SELF |
MSM, Directly-Assisted |
2019 |
12,383 |
| HTS_SELF |
PWID, Directly-Assisted |
2019 |
4,953 |
| HTS_SELF |
Unassisted |
2019 |
41,277 |
| HTS_SELF |
Unassisted - Other |
2019 |
4,128 |
| HTS_SELF |
Unassisted - Self |
2019 |
20,638 |
| HTS_SELF |
Unassisted - Sex Partner |
2019 |
16,511 |
| HTS_TST |
15-19, Female, Negative |
2019 |
90 |
| HTS_TST |
15-19, Male, Negative |
2019 |
43 |
| HTS_TST |
20-24, Female, Negative |
2019 |
317 |
| HTS_TST |
20-24, Male, Negative |
2019 |
139 |
| HTS_TST |
25-29, Female, Negative |
2019 |
670 |
| HTS_TST |
25-29, Female, Negative |
2019 |
26 |
| HTS_TST |
25-29, Female, Negative |
2019 |
72 |
| HTS_TST |
25-29, Female, Negative |
2019 |
4,461 |
| HTS_TST |
25-29, Female, Negative |
2019 |
4,389 |
| HTS_TST |
25-29, Female, Negative |
2019 |
17 |
| HTS_TST |
25-29, Female, Negative |
2019 |
23 |
| HTS_TST |
25-29, Male, Negative |
2019 |
1,402 |
| HTS_TST |
25-29, Male, Negative |
2019 |
561 |
| HTS_TST |
25-29, Male, Negative |
2019 |
50 |
| HTS_TST |
25-29, Male, Negative |
2019 |
152 |
| HTS_TST |
25-29, Male, Negative |
2019 |
9,352 |
| HTS_TST |
25-29, Male, Negative |
2019 |
38 |
| HTS_TST |
25-29, Male, Negative |
2019 |
27 |
| HTS_TST |
30-34, Female, Negative |
2019 |
766 |
| HTS_TST |
30-34, Female, Negative |
2019 |
28 |
| HTS_TST |
30-34, Female, Negative |
2019 |
83 |
| HTS_TST |
30-34, Female, Negative |
2019 |
5,098 |
| HTS_TST |
30-34, Female, Negative |
2019 |
4,389 |
| HTS_TST |
30-34, Female, Negative |
2019 |
20 |
| HTS_TST |
30-34, Female, Negative |
2019 |
19 |
| HTS_TST |
30-34, Male, Negative |
2019 |
1,685 |
| HTS_TST |
30-34, Male, Negative |
2019 |
63 |
| HTS_TST |
30-34, Male, Negative |
2019 |
182 |
| HTS_TST |
30-34, Male, Negative |
2019 |
11,218 |
| HTS_TST |
30-34, Male, Negative |
2019 |
46 |
| HTS_TST |
30-34, Male, Negative |
2019 |
31 |
| HTS_TST |
35-39, Female, Negative |
2019 |
190 |
| HTS_TST |
35-39, Female, Negative |
2019 |
8 |
| HTS_TST |
35-39, Female, Negative |
2019 |
21 |
| HTS_TST |
35-39, Female, Negative |
2019 |
1,278 |
| HTS_TST |
35-39, Female, Negative |
2019 |
4,389 |
| HTS_TST |
35-39, Female, Negative |
2019 |
24 |
| HTS_TST |
35-39, Male, Negative |
2019 |
1,685 |
| HTS_TST |
35-39, Male, Negative |
2019 |
63 |
| HTS_TST |
35-39, Male, Negative |
2019 |
182 |
| HTS_TST |
35-39, Male, Negative |
2019 |
11,218 |
| HTS_TST |
35-39, Male, Negative |
2019 |
46 |
| HTS_TST |
35-39, Male, Negative |
2019 |
43 |
| HTS_TST |
40-49, Female, Negative |
2019 |
190 |
| HTS_TST |
40-49, Female, Negative |
2019 |
8 |
| HTS_TST |
40-49, Female, Negative |
2019 |
21 |
| HTS_TST |
40-49, Female, Negative |
2019 |
1,278 |
| HTS_TST |
40-49, Female, Negative |
2019 |
4,389 |
| HTS_TST |
40-49, Female, Negative |
2019 |
19 |
| HTS_TST |
40-49, Male, Negative |
2019 |
35 |
| HTS_TST |
40-49, Male, Negative |
2019 |
560 |
| HTS_TST |
40-49, Male, Negative |
2019 |
20 |
| HTS_TST |
40-49, Male, Negative |
2019 |
61 |
| HTS_TST |
40-49, Male, Negative |
2019 |
3,735 |
| HTS_TST |
40-49, Male, Negative |
2019 |
16 |
| HTS_TST |
50+, Male, Negative |
2019 |
2 |
| HTS_TST |
By Key Population: FSW, Negative |
2019 |
10,510 |
| HTS_TST |
By Key Population: MSM, Negative |
2019 |
1,319 |
| HTS_TST |
By Key Population: PWID, Negative |
2019 |
3,254 |
| HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2019 |
264,475 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 10-14, Negative |
2019 |
20 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 15-19, Negative |
2019 |
2,394 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 20-24, Negative |
2019 |
10,652 |
| HTS_TST |
Service Delivery Point (Facility) ANC: 50+, Negative |
2019 |
2 |
| HTS_TST |
Service Delivery Point (Facility) Index: <1, Negative |
2019 |
101 |
| HTS_TST |
Service Delivery Point (Facility) Index: 1-9, Negative |
2019 |
277 |
| HTS_TST |
Service Delivery Point (Facility) Index: 10-14, Female, Negative |
2019 |
66 |
| HTS_TST |
Service Delivery Point (Facility) Index: 10-14, Male, Negative |
2019 |
54 |
| HTS_TST |
Service Delivery Point (Facility) Index: 15-19, Female, Negative |
2019 |
118 |
| HTS_TST |
Service Delivery Point (Facility) Index: 15-19, Male, Negative |
2019 |
55 |
| HTS_TST |
Service Delivery Point (Facility) Index: 20-24, Female, Negative |
2019 |
402 |
| HTS_TST |
Service Delivery Point (Facility) Index: 20-24, Male, Negative |
2019 |
393 |
| HTS_TST |
Service Delivery Point (Facility) Index: 50+, Female, Negative |
2019 |
3 |
| HTS_TST |
Service Delivery Point (Facility) Index: 50+, Male, Negative |
2019 |
10 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative |
2019 |
349 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative |
2019 |
166 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative |
2019 |
1,202 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative |
2019 |
532 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 50+, Female, Negative |
2019 |
10 |
| HTS_TST |
Service Delivery Point (Facility) Inpatient: 50+, Male, Negative |
2019 |
30 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 1-9, Negative |
2019 |
1,248 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative |
2019 |
301 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative |
2019 |
252 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative |
2019 |
15,863 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative |
2019 |
15,920 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative |
2019 |
74,160 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative |
2019 |
32,809 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative |
2019 |
636 |
| HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative |
2019 |
1,869 |
| HTS_TST |
Service Delivery Point (Facility) Pediatric : <5 Negative |
2019 |
1,001 |
| HTS_TST |
Service Delivery Point (Facility) TB: 1-9, Negative |
2019 |
12 |
| HTS_TST |
Service Delivery Point (Facility) TB: 10-14, Female, Negative |
2019 |
14 |
| HTS_TST |
Service Delivery Point (Facility) TB: 10-14, Male, Negative |
2019 |
13 |
| HTS_TST |
Service Delivery Point (Facility) TB: 15-19, Female, Negative |
2019 |
22 |
| HTS_TST |
Service Delivery Point (Facility) TB: 15-19, Male, Negative |
2019 |
26 |
| HTS_TST |
Service Delivery Point (Facility) TB: 20-24, Female, Negative |
2019 |
22 |
| HTS_TST |
Service Delivery Point (Facility) TB: 20-24, Male, Negative |
2019 |
27 |
| HTS_TST |
Service Delivery Point (Facility) TB: 50+, Female, Negative |
2019 |
17 |
| HTS_TST |
Service Delivery Point (Facility) TB: 50+, Male, Negative |
2019 |
30 |
| HTS_TST |
Service Delivery Point (Facility) VCT: <1, Negative |
2019 |
31 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 1-9, Negative |
2019 |
83 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 10-14, Female, Negative |
2019 |
19 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 10-14, Male, Negative |
2019 |
16 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 15-19, Female, Negative |
2019 |
3,231 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 15-19, Male, Negative |
2019 |
1,539 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 20-24, Female, Negative |
2019 |
11,134 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 20-24, Male, Negative |
2019 |
4,924 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 50+, Female, Negative |
2019 |
96 |
| HTS_TST |
Service Delivery Point (Facility) VCT: 50+, Male, Negative |
2019 |
279 |
| HTS_TST |
Service Delivery Point (Facility) VMMC: 10-14, Negative |
2019 |
561 |
| HTS_TST |
Service Delivery Point (Facility) VMMC: 15-19, Negative |
2019 |
841 |
| HTS_TST |
Service Delivery Point (Facility) VMMC: 20-24, Negative |
2019 |
841 |
| HTS_TST |
Service Delivery Point (Facility)Other PITC: <1, Negative |
2019 |
460 |
| HTS_TST_POS |
20-24, Female, Positive |
2019 |
2 |
| HTS_TST_POS |
20-24, Male, Positive |
2019 |
2 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
11 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
7 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
61 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
452 |
| HTS_TST_POS |
25-29, Female, Positive |
2019 |
10 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
24 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
15 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
12 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
128 |
| HTS_TST_POS |
25-29, Male, Positive |
2019 |
12 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
16 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
8 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
68 |
| HTS_TST_POS |
30-34, Female, Positive |
2019 |
10 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
31 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
20 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
154 |
| HTS_TST_POS |
30-34, Male, Positive |
2019 |
15 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
19 |
| HTS_TST_POS |
35-39, Female, Positive |
2019 |
10 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
31 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
20 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
154 |
| HTS_TST_POS |
35-39, Male, Positive |
2019 |
22 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
3 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
19 |
| HTS_TST_POS |
40-49, Female, Positive |
2019 |
10 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
18 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
11 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
8 |
| HTS_TST_POS |
40-49, Male, Positive |
2019 |
51 |
| HTS_TST_POS |
By Key Population: FSW, Positive |
2019 |
565 |
| HTS_TST_POS |
By Key Population: MSM, Positive |
2019 |
224 |
| HTS_TST_POS |
By Key Population: PWID, Positive |
2019 |
60 |
| HTS_TST_POS |
Service Delivery Point (Facility) ANC: 15-19, Positive |
2019 |
30 |
| HTS_TST_POS |
Service Delivery Point (Facility) ANC: 20-24, Positive |
2019 |
213 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: <1, Positive |
2019 |
2 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 1-9, Positive |
2019 |
6 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 10-14, Female, Positive |
2019 |
2 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 10-14, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 15-19, Female, Positive |
2019 |
34 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 15-19, Male, Positive |
2019 |
16 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 20-24, Female, Positive |
2019 |
113 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 20-24, Male, Positive |
2019 |
54 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 50+, Female, Positive |
2019 |
1 |
| HTS_TST_POS |
Service Delivery Point (Facility) Index: 50+, Male, Positive |
2019 |
3 |
| HTS_TST_POS |
Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive |
2019 |
2 |
| HTS_TST_POS |
Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive |
2019 |
7 |
| HTS_TST_POS |
Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive |
2019 |
3 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: <1, Positive |
2019 |
4 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 1-9, Positive |
2019 |
11 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive |
2019 |
1 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive |
2019 |
1 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive |
2019 |
210 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive |
2019 |
216 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive |
2019 |
1,002 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive |
2019 |
446 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive |
2019 |
13 |
| HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive |
2019 |
22 |
| HTS_TST_POS |
Service Delivery Point (Facility) Pediatric : <5 Positive |
2019 |
2 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 1-9, Positive |
2019 |
6 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 10-14, Female, Positive |
2019 |
7 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 10-14, Male, Positive |
2019 |
7 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 15-19, Female, Positive |
2019 |
11 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 15-19, Male, Positive |
2019 |
13 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 20-24, Female, Positive |
2019 |
11 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 20-24, Male, Positive |
2019 |
13 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 50+, Female, Positive |
2019 |
8 |
| HTS_TST_POS |
Service Delivery Point (Facility) TB: 50+, Male, Positive |
2019 |
15 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 1-9, Positive |
2019 |
1 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 15-19, Female, Positive |
2019 |
60 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 15-19, Male, Positive |
2019 |
28 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 20-24, Female, Positive |
2019 |
205 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 20-24, Male, Positive |
2019 |
91 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 50+, Female, Positive |
2019 |
2 |
| HTS_TST_POS |
Service Delivery Point (Facility) VCT: 50+, Male, Positive |
2019 |
5 |
| HTS_TST_POS |
Service Delivery Point (Facility) VMMC: 10-14, Positive |
2019 |
15 |
| HTS_TST_POS |
Service Delivery Point (Facility) VMMC: 15-19, Positive |
2019 |
22 |
| HTS_TST_POS |
Service Delivery Point (Facility) VMMC: 20-24, Positive |
2019 |
22 |
| KP_MAT |
Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months |
2019 |
2,400 |
| KP_MAT |
Sex: Female |
2019 |
1,000 |
| KP_MAT |
Sex: Male |
2019 |
1,400 |
| KP_MAT |
Sum of Sex disaggregates |
2019 |
2,400 |
| KP_PREV |
By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
42,164 |
| KP_PREV |
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
682 |
| KP_PREV |
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
7,117 |
| KP_PREV |
By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
432 |
| KP_PREV |
By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
3,727 |
| KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2019 |
54,122 |
| PMTCT_ART |
Already on ART at beginning of current pregnancy |
2019 |
1,018 |
| PMTCT_ART |
New on ART |
2019 |
665 |
| PMTCT_ART |
Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy |
2019 |
1,683 |
| PMTCT_ART |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2019 |
32,180 |
| PMTCT_EID |
By infants who received their first virologic HIV test between 2 and 12 months of age |
2019 |
32 |
| PMTCT_EID |
Number of infants who had a virologic HIV test within 12 months of birth during the reporting period |
2019 |
32 |
| PMTCT_EID |
Sum of Infant Age disaggregates |
2019 |
32 |
| PMTCT_STAT |
25-29, Female |
2019 |
4,675 |
| PMTCT_STAT |
25-29, Female, Known at Entry Positive |
2019 |
209 |
| PMTCT_STAT |
25-29, Female, Newly Identified Negative |
2019 |
4,365 |
| PMTCT_STAT |
25-29, Female, Newly Identified Positive |
2019 |
97 |
| PMTCT_STAT |
30-34, Female |
2019 |
4,630 |
| PMTCT_STAT |
30-34, Female, Known at Entry Positive |
2019 |
209 |
| PMTCT_STAT |
30-34, Female, Newly Identified Negative |
2019 |
4,365 |
| PMTCT_STAT |
30-34, Female, Newly Identified Positive |
2019 |
97 |
| PMTCT_STAT |
35-39, Female |
2019 |
4,675 |
| PMTCT_STAT |
35-39, Female, Known at Entry Positive |
2019 |
209 |
| PMTCT_STAT |
35-39, Female, Newly Identified Negative |
2019 |
4,365 |
| PMTCT_STAT |
35-39, Female, Newly Identified Positive |
2019 |
97 |
| PMTCT_STAT |
40-49, Female |
2019 |
4,675 |
| PMTCT_STAT |
40-49, Female, Known at Entry Positive |
2019 |
209 |
| PMTCT_STAT |
40-49, Female, Newly Identified Negative |
2019 |
4,365 |
| PMTCT_STAT |
40-49, Female, Newly Identified Positive |
2019 |
97 |
| PMTCT_STAT |
By Age (Numerator): 10-14 |
2019 |
23 |
| PMTCT_STAT |
By Age (Numerator): 15-19 |
2019 |
2,464 |
| PMTCT_STAT |
By Age (Numerator): 20-24 |
2019 |
11,036 |
| PMTCT_STAT |
By Age (Numerator): 50+ |
2019 |
2 |
| PMTCT_STAT |
By Number of known positives: 15-19 |
2019 |
30 |
| PMTCT_STAT |
By Number of known positives: 20-24 |
2019 |
193 |
| PMTCT_STAT |
By Number of new negative: 10-14 |
2019 |
20 |
| PMTCT_STAT |
By Number of new negative: 15-19 |
2019 |
2,380 |
| PMTCT_STAT |
By Number of new negative: 20-24 |
2019 |
10,580 |
| PMTCT_STAT |
By Number of new negative: 50+ |
2019 |
2 |
| PMTCT_STAT |
By Number of new positives: 15-19 |
2019 |
51 |
| PMTCT_STAT |
By Number of new positives: 20-24 |
2019 |
240 |
| PMTCT_STAT |
Number of new ANC and L&D clients |
2019 |
32,691 |
| PMTCT_STAT |
Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) |
2019 |
32,180 |
| PMTCT_STAT_den |
25-29, Female |
2019 |
4,728 |
| PMTCT_STAT_den |
30-34, Female |
2019 |
4,728 |
| PMTCT_STAT_den |
35-39, Female |
2019 |
4,728 |
| PMTCT_STAT_den |
40-49, Female |
2019 |
4,728 |
| PMTCT_STAT_den |
By Age (Denominator): <15-19 |
2019 |
2,741 |
| PMTCT_STAT_den |
By Age (Denominator): 10-14 |
2019 |
18 |
| PMTCT_STAT_den |
By Age (Denominator): 20-24 |
2019 |
11,020 |
| PrEP_NEW |
25-29, Female |
2019 |
44 |
| PrEP_NEW |
25-29, Male |
2019 |
19 |
| PrEP_NEW |
30-34, Female |
2019 |
32 |
| PrEP_NEW |
30-34, Male |
2019 |
25 |
| PrEP_NEW |
35-39, Female |
2019 |
31 |
| PrEP_NEW |
35-39, Male |
2019 |
25 |
| PrEP_NEW |
40-49, Female |
2019 |
31 |
| PrEP_NEW |
40-49, Male |
2019 |
19 |
| PrEP_NEW |
Female 15-19 |
2019 |
75 |
| PrEP_NEW |
Female 20-24 |
2019 |
256 |
| PrEP_NEW |
Female 50+ |
2019 |
12 |
| PrEP_NEW |
FSW |
2019 |
87 |
| PrEP_NEW |
Male 15-19 |
2019 |
6 |
| PrEP_NEW |
Male 20-24 |
2019 |
37 |
| PrEP_NEW |
Male 50+ |
2019 |
12 |
| PrEP_NEW |
MSM |
2019 |
44 |
| PrEP_NEW |
Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection |
2019 |
624 |
| TB_ART |
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2019 |
247 |
| TB_ART |
Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2019 |
321 |
| TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2019 |
568 |
| TB_PREV |
By Age/Sex (Numerator): <15, Female |
2019 |
85 |
| TB_PREV |
By Age/Sex (Numerator): <15, Male |
2019 |
98 |
| TB_PREV |
By Age/Sex (Numerator): 15+, Female |
2019 |
1,585 |
| TB_PREV |
By Age/Sex (Numerator): 15+, Male |
2019 |
895 |
| TB_PREV |
The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period |
2019 |
2,663 |
| TB_PREV |
The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) |
2019 |
3,131 |
| TB_PREV_den |
By Age/Sex (Denominator): <15, Female |
2019 |
108 |
| TB_PREV_den |
By Age/Sex (Denominator): <15, Male |
2019 |
118 |
| TB_PREV_den |
By Age/Sex (Denominator): 15+, Female |
2019 |
1,858 |
| TB_PREV_den |
By Age/Sex (Denominator): 15+, Male |
2019 |
1,047 |
| TB_PREV_den |
IPT, Life-long ART, New, Positive |
2019 |
3,131 |
| TB_STAT |
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
57 |
| TB_STAT |
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
705 |
| TB_STAT |
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
69 |
| TB_STAT |
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
1,049 |
| TB_STAT |
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period |
2019 |
1,880 |
| TB_STAT |
Total number of registered new and relapsed TB cases, during the reporting period |
2019 |
1,877 |
| TB_STAT_den |
Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
66 |
| TB_STAT_den |
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
694 |
| TB_STAT_den |
Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
69 |
| TB_STAT_den |
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
1,048 |
| TX_CURR |
25-29, Female, Positive |
2019 |
4,240 |
| TX_CURR |
25-29, Male, Positive |
2019 |
1,322 |
| TX_CURR |
30-34, Female, Positive |
2019 |
3,217 |
| TX_CURR |
30-34, Male, Positive |
2019 |
2,065 |
| TX_CURR |
35-39, Female, Positive |
2019 |
3,217 |
| TX_CURR |
35-39, Male, Positive |
2019 |
2,065 |
| TX_CURR |
40-49, Female, Positive |
2019 |
2,193 |
| TX_CURR |
40-49, Male, Positive |
2019 |
2,065 |
| TX_CURR |
Age/Sex: <1 |
2019 |
15 |
| TX_CURR |
Age/Sex: <1-9 |
2019 |
476 |
| TX_CURR |
Age/Sex: 10-14 Female |
2019 |
250 |
| TX_CURR |
Age/Sex: 10-14 Male |
2019 |
243 |
| TX_CURR |
Age/Sex: 15-19 Female |
2019 |
673 |
| TX_CURR |
Age/Sex: 15-19 Male |
2019 |
365 |
| TX_CURR |
Age/Sex: 20-24 Female |
2019 |
1,880 |
| TX_CURR |
Age/Sex: 20-24 Male |
2019 |
484 |
| TX_CURR |
Age/Sex: 50+ Female |
2019 |
1,755 |
| TX_CURR |
Age/Sex: 50+ Male |
2019 |
745 |
| TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
27,270 |
| TX_CURR |
Sum of age/sex disaggregates |
2019 |
1,038 |
| TX_NEW |
25-29, Female, Positive |
2019 |
143 |
| TX_NEW |
25-29, Male, Positive |
2019 |
259 |
| TX_NEW |
30-34, Female, Positive |
2019 |
159 |
| TX_NEW |
30-34, Male, Positive |
2019 |
310 |
| TX_NEW |
35-39, Female, Positive |
2019 |
42 |
| TX_NEW |
35-39, Male, Positive |
2019 |
310 |
| TX_NEW |
40-49, Female, Positive |
2019 |
42 |
| TX_NEW |
40-49, Male, Positive |
2019 |
103 |
| TX_NEW |
Breastfeeding status |
2019 |
36 |
| TX_NEW |
By Age/Sex: <1 |
2019 |
51 |
| TX_NEW |
By Age/Sex: 1-9 |
2019 |
24 |
| TX_NEW |
By Age/Sex: 10-14 Female |
2019 |
5 |
| TX_NEW |
By Age/Sex: 10-14 Male |
2019 |
7 |
| TX_NEW |
By Age/Sex: 15-19 Female |
2019 |
509 |
| TX_NEW |
By Age/Sex: 15-19 Male |
2019 |
191 |
| TX_NEW |
By Age/Sex: 20-24 Female |
2019 |
1,746 |
| TX_NEW |
By Age/Sex: 20-24 Male |
2019 |
585 |
| TX_NEW |
By Age/Sex: 50+ Female |
2019 |
13 |
| TX_NEW |
By Age/Sex: 50+ Male |
2019 |
54 |
| TX_NEW |
FSW |
2019 |
106 |
| TX_NEW |
MSM |
2019 |
48 |
| TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
4,561 |
| TX_NEW |
Pregnancy status |
2019 |
550 |
| TX_NEW |
Sum of Age/Sex disaggregates |
2019 |
3,110 |
| TX_NEW |
TG |
2019 |
10 |
| TX_PVLS |
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months |
2019 |
26,472 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Female Routine |
2019 |
463 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted |
2019 |
24 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Male Routine |
2019 |
445 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted |
2019 |
23 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine |
2019 |
15,838 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted |
2019 |
835 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine |
2019 |
8,402 |
| TX_PVLS_den |
Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted |
2019 |
442 |
| TX_PVLS_den |
Denominator: Indication: Routine |
2019 |
25,149 |
| TX_PVLS_den |
Denominator: Indication: Targeted |
2019 |
1,323 |
| TX_RET |
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
126 |
| TX_RET |
Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
57 |
| TX_RET |
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
5,109 |
| TX_RET |
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |
2019 |
2,319 |
| TX_RET |
Number of adults and children who are still alive and on treatment at 12 months after initiating ART |
2019 |
7,610 |
| TX_RET |
Numerator by Status: Breastfeeding |
2019 |
144 |
| TX_RET |
Numerator by Status: Pregnant |
2019 |
692 |
| TX_RET |
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |
2019 |
8,196 |
| TX_RET_den |
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
122 |
| TX_RET_den |
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
57 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
5,519 |
| TX_RET_den |
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
2019 |
2,500 |
| TX_RET_den |
Denominator by Status: Breastfeeding |
2019 |
144 |
| TX_RET_den |
Denominator by Status: Pregnant |
2019 |
692 |
| TX_TB |
Number of ART patients who were screened for TB at least once during the reporting period |
2019 |
27,270 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex: <15, Female |
2019 |
550 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex: <15, Male |
2019 |
434 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex:15+, Female |
2019 |
17,174 |
| TX_TB_den |
Denominator: By Aggregated Age/Sex:15+, Male |
2019 |
9,116 |
| TX_TB_den |
Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay |
2019 |
593 |
| TX_TB_den |
Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only |
2019 |
270 |
| TX_TB_den |
Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease |
2019 |
891 |
